

Aerobiotix and Public Health and Social Services Emergency Fund (CARES Act)

There have been questions whether the costs of acquisition and use of Aerobiotix air decontamination products constitute eligible expenses under the Public Health and Social Services Emergency Fund (CARES Act).

The terms and conditions of the relief fund state that the funds can only be used “to prevent, prepare for, and respond to coronavirus, and that the payment shall reimburse the recipient only for health care related expenses or lost revenues that are attributable to coronavirus.” Additionally, the funds “cannot be used to reimburse expenses or losses that have been reimbursed from other sources or that other sources are obligated to reimburse.”

Eligible recipients for funding must have billed Medicare in 2019; provided after January 31, 2020 diagnoses, testing, or care for individuals with possible or actual cases of COVID-19; and are not currently terminated from participation in federal health programs.

Aerobiotix air decontamination systems are FDA regulated medical devices which use a combination of HEPA filtration and UV radiation to decontaminate the airborne environment, creating an area free of pathogens, including validation for removal of viral contamination. As such:

- Aerobiotix devices satisfy the requirement to “prevent, prepare for, and respond” to the coronavirus pandemic;
- Aerobiotix devices are not patient-specific or prescriptive devices, and are therefore not reimbursable through other sources, such as private health insurance, Medicare, Medicaid or other insurance providers.

Therefore, it is our position that Aerobiotix devices **ARE** an eligible, reimbursable expense under the Public Health and Social Services Emergency Fund (CARES Act).

Please contact us at info@aerobiotix.com for any further questions.

